重组人血管内皮抑素联合吉西他滨治疗铂类耐药复发卵巢癌的临床观察

Clinical observation of recombinant human endostatin combined with gemcitabine in the treatment of platinum-resistant recurrent ovarian cancer

目的探讨重组人血管内皮抑素(恩度)联合吉西他滨治疗铂类耐药复发卵巢癌的疗效及安全性。方法将64例铂类耐药复发卵巢癌患者随机分为两组,试验组33例接受恩度联合吉西他滨方案,对照组31例接受单药吉西他滨方案,比较两组临床疗效、不良反应和生活质量。结果试验组与对照组的客观有效率(39.3%vs16.1%)、疾病控制率(75.8%vs 41.9%)、中位无疾病进展生存期(6.5个月vs 3.1个月)比较差异有统计学意义(P<0.05);两组中位生存期(13.7个月vs 10.9个月)、不良反应和生活质量比较差异均无统计学意义(P>0.05)。结论恩度联合吉西他滨方案治疗铂类耐药复发卵巢癌,可提高患者的近期疗效及中位无疾病进展生存期,且不增加不良反应发生率。

Objective To evaluate the efficacy and safety of recombinant human endostatin（endostar）in combination with gemcitabine in the treatment of platinum-resistant recurrent ovarian cancer.Methods A total of 64 patients with platinum-resistant recurrent ovarian cancer were randomly divided into the experimental group （n =33 ）and control group （n=3 1 ）.The experimental group received endostar plus gemcitabine while the control group gemcitabine regi-men alone.The efficacy,adverse reactions and quality of life were compared.Results Statistically significant differ-ences were observed in the objective response rate,disease control rate and median progression-free survival between the experimental group and control group （39.3%vs 16.1%,75.8%vs 41.9%,6.5 months vs 3.1 months,P0.05 ）.Conclusion Endostar in combination with gemcitabine significantly improves short-term effect and median progression-free survival in patients with platinum-resistant recurrent ovarian cancer without increasing the incidence of adverse effects.